BBI-940 + Fulvestrant for Breast Cancer
(KOMODO-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Who Is on the Research Team?
Robert C. Doebele, MD, PhD
Principal Investigator
Boundless Bio, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- BBI-940
- Fulvestrant
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Participants receive BBI-940 given alone in multiple sequential dose escalation cohorts. BBI-940 is given orally in repeated 28-day cycles.
Participants receive BBI-940 given alone at the recommended dose for expansion (RDE). BBI-940 is given orally in repeated 28-day cycles.
Participants receive BBI-940 given alone at the recommended dose for expansion (RDE). BBI-940 is given orally in repeated 28-day cycles.
Participants receive BBI-940 in combination with fulvestrant. BBI-940 is given orally in repeated 28-day cycles at one of multiple potential dose levels.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boundless Bio
Lead Sponsor
Boundless Bio, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.